Bristol Myers Squibb (BMY) has sought FDA approval for the expanded use of Krazati and a decision is due on June 21, 2024.Krazati in combination with Cetuximab is proposed for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.The initial FDA approval for Krazati was granted in December 2022, in the indication of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, under accelerated approval pathway.Krazati came under Bristol Myers’ fold following the acquisition of Mirati Therapeutics in October 2023.The drug brought home sales of $21 million for Bristol Myers in the first quarter of 2024.BMY closed Wednesday’s trading at $40.25, down 0.59%.